Roswell Park and Local HMO Use Claims Data to Study Regional Breast Cancer Care Patterns to Evaluate Quality

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

BUFFALO, NY-One use of cancer practice guidelines will be to raise the standard of care in a community and create partnerships between cancer centers and payers, Stephen Edge, MD, told the President’s Cancer Panel.

BUFFALO, NY—One use of cancer practice guidelines will be to raise the standard of care in a community and create partnerships between cancer centers and payers, Stephen Edge, MD, told the President’s Cancer Panel.

Dr. Edge, chief of Breast Surgery at Roswell Park, described a collaborative effort among Roswell Park; Independent Health, Inc. (a not-for-profit HMO in Western New York); and a panel of community physicians to examine the quality of breast cancer care in the region, using administrative claims data from Independent Health, and explore ways to improve current practices.

“We hypothesized that claims data would show a cross section of breast cancer care in Western New York. We wanted to determine patterns of care to evaluate quality, including comparison of care in the region with the established practice guidelines of the National Comprehensive Cancer Network,” Dr. Edge said.

Patients were identified from claims data of breast procedures and diagnoses over a 2-year period from 1995 to 1997, plus 6 months of subsequent insurance claims. The type of care was determined from the claims. Cancer stage was determined by obtaining surgery and pathology reports through the HMO.

One area of quality evaluation was the rate of positive findings on mammo-graphic-directed breast biopsy. The study showed 2,798 biopsies—2,376 patients with no cancer and 422 with a confirmed cancer diagnosis. In the optimal practice setting, 25% to 30% of these biopsies should be positive for cancer. Claims data demonstrated that in Western New York, about 18% of mammographic-directed biopsies were positive. However, the rate of positive biopsy varied significantly among individual radiologists and surgeons, ranging from 7% to 39%.

Other measures of quality care under study include the rate of breast-conserving surgery (about 60%)and the number of second breast surgeries to re-excise additional tissue due to positive margins.

“Optimally, our goal is to have only one surgical procedure on a breast to remove malignancy. If we could eliminate some of these secondary surgeries, we could save a great deal of money and anxiety in this population,” Dr. Edge said.

Overall, the study has shown the feasibility of studying practice patterns in breast cancer using claims data, and the potential applicability of the method to other cancers. The next step, he said, is to complete the review of data and comparison with NCCN guidelines. Feedback of these results to providers should assist in ongoing quality improvement.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content